In drug development, trust in the models utilized is critical. Even when a model demonstrates acceptable predictive performance, certain recurring issues can significantly reduce reviewer confidence.
Quantification of the Exposure of Consumers and Hairdressers to Formaldehyde and Oxalic Acid After Application of Hair Straightening Products Containing Glyoxylic Acid
Glyoxylic acid (GA), the active ingredient of heat-activated hair straightening products (GHSPs) has been discussed in the context of acute kidney injury (AKI) via oxalic acid (OA) crystal formation and of heat-decomposition resulting in release of formaldehyde.
A Multivariate Ann-CCD Integrative Model Using Cellulose Based Polymers for the Development of Osmotically Controlled Push-Pull Dexibuprofen Tablets and Its Predictive Pharmacokinetic Modeling
The biocompatible macromolecules play a pivotal role in enhancing the performance of various drug delivery systems.
In Silico Predictions for ADME and Toxicology
Advances in computational modeling are transforming how scientists predict a compound’s Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) profiles.
In Silico Toxicokinetics
Absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling is a major driver of drug success, controlling pharmacokinetic behavior, therapeutic effectiveness, and safety.
In Silico Prediction of Solubility, Permeability, and Metabolism
This chapter presents a comprehensive review of in silico techniques for the prediction of solubility, permeability, and metabolism—critical determinants of drug candidates’ pharmacokinetic and safety profiles during drug discovery and development.
Physiologically Based Pharmacokinetic Modeling of Cefotaxime To Inform Pediatric Dosing in Renal Impairment
Cefotaxime (CFT) is a broad spectrum, third-generation cephalosporin antibiotic prescribed for the treatment of severe infections, yet dosing guidelines for pediatric with renal impairment is scarce.
Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026.
University+ Flyer
Empowering the learning, application, and publication of modeling & simulation globally.
Why Next-Generation Mechanistic Models will Transform Drug Discovery: Integrating Efficacy and Safety
Drug discovery remains constrained by high attrition rates and the fragmented evaluation of exposure, efficacy, and safety.
Why Mechanistic Modeling has Become the Preferred Framework for Modern Generic Development
When the question is mechanism, deconvolution estimates. PBBM explains.
Animal-Free Skin Sensitization Testing: In Chemico and In Silico Integrated Approach
The increasing prohibition of animal testing for cosmetic products has driven the development of alternative approaches to ensure consumer safety.
In vitro Drug-Like Properties Evaluation of the New Positive Allosteric Modulators of EAAT2 Glutamate Transporter
Evaluation of drug-like properties in vitro is critical in identifying viable candidates for new central nervous system (CNS) drugs.
Physiologically Based Pharmacokinetic and Drug–Drug Interaction Modeling of Efavirenz, Etravirine, and Saquinavir in Prostate Cancer
Prostate cancer remains one of the most prevalent malignancies worldwide, with high mortality in advanced and metastatic stages.
Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
New capabilities connect AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development
Keeping Pace with Obesity Drug Development: Recent Advances in OBESITYsym®
In this webinar, Dr. Scott Q. Siler, Chief Science Officer of QSP, discusses how quantitative systems pharmacology can help improve the efficiency of obesity drug development.
The Scientist, Amplified: Why Agentic Drug Development Needs a Foundation It Can Trust
The question is not whether agentic AI is coming. It is this: can you stake a regulatory submission on it?
Simulations Plus to Be Acquired by Altaris For Approximately $375 Million
Stockholders to Receive $18.50 Per Share in Cash Representing a 26% Premium to 60-day Volume-Weighted Average Price
Transaction to Strengthen Simulations Plus and Accelerate Growth Through Anticipated Combination with Chemical Computing Group
When Does Model Interpretability Matter Most?
Model interpretability is not uniformly critical across all stages of model development; however, it becomes essential at key decision points where scientific understanding must support regulatory confidence.